Hypoglycemia and Hyperglycemia Associated with Gatifloxacin Use in Elderly Patients

References

1. ↵
   Oliphant CM, Green GM. Quinolones. A comprehensive review. Am Fam Physician 2002; 65: 455–64.

   OpenUrlPubMedWeb of Science
2. ↵
   Anonymous. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther 2000; 42: 15–7.

   OpenUrlPubMedWeb of Science
3. ↵
   Grasela D, Lacreta F, Kollia G, Randall D, Stoltz R, Berger S. Lack of effect of multiple-dose gatifloxacin (GAT) on oral glucose tolerance (OGTT), glucose and insulin homeostasis, and glyburide pharmacokinetics (PK) in patients with type II non-insulin dependent diabetes mellitus (NIDDM) [abstract]. In: Proceedings and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, California. Washington, DC: American Society for Microbiology, 1999: 11.
4. ↵
   Package insert. Tequin (gatifloxacin). Princeton, NJ: Bristol-Meyers Squibb Company, 2002 April.
5. ↵
   Package insert. Tequin (gatifloxacin). Princeton, NJ: Bristol-Meyers Squibb Company, 2000 February.
6. ↵
   Gajjar DA, LaCreta FP, Kollia GD. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000; 20: 76S–86S.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study for the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000; 20: 49S–58S).

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin Infect Dis 2000; 31 Suppl 2: S51–8.
9. ↵
   Rajagopalan S, Yoshikawa TT. Antimicrobial therapy in the elderly. Med Clin North Am 2001; 85: 133–47.

   OpenUrlCrossRefPubMedWeb of Science